Glucotrack closes $5.5 million financing tied to bridge notes and PIPE deal

Glucotrack, Inc. announced on August 4, 2026 that it had signed definitive agreements for roughly $5.5 million in financing from participating institutional investors, split between a $2.0 million equity financing priced at $0.75 per unit and a $3.5 million follow-on investment structured as convertible debt.¹

Each equity unit in the offering is made up of one share of common stock or its equivalent and a five-year warrant carrying a $1.50 exercise price.¹

On the debt side, the company issued new senior secured convertible promissory notes to a group of investors joining its existing bridge financing. These "Follow-On Bridge Notes" carry a principal amount of $3,500,000 but a face value of $4,487,179, reflecting a 22% original issue discount.¹ The notes bear 8% annual interest and mature nine months from July 14, 2026,¹ the date tied to the original bridge financing.

The notes are not convertible until Glucotrack secures stockholder approval under Nasdaq's rules, and once cleared, they convert at the lower of the Nasdaq Minimum Price or 80% of the lowest daily volume-weighted average price over the prior 15 trading days, subject to a floor of 20% of the Nasdaq Minimum Price.¹

Separately, in the Interim PIPE transaction, the company issued 2,666,667 pre-funded warrants alongside common stock purchase warrants for the same number of shares, priced to generate $2,000,000 in gross proceeds, with the common warrants carrying a $1.50 per-share exercise price.¹

Glucotrack said E.F. Hutton & Co. served as exclusive advisor to Lōkahi Therapeutics, a subsidiary of Glucotrack, on the transaction.¹ CEO Erik Emerson said the financing "strengthens our balance sheet, provides additional growth capital, and reflects confidence in our long-term strategy."